NEW YORK (GenomeWeb News) – German biotech firm MorphoSys today announced an agreement between its recently acquired subsidiary Sloning BioTechnology and Pfizer for use of Sloning's synthetic biology technology.
Sloning will install its Slonomics platform at Pfizer's subsidiary Rinat Neuroscience in South San Francisco, Calif. Sloning will also provide training and use of the platform. Rinat has been using Sloning's services since 2009, Jaume Pons, chief scientific officer for Rinat, said in a statement.
Sloning will receive an upfront payment for an undisclosed amount in 2010, and licensing fees of the patent lifetime of the Slonomics technology, MorphoSys said.
Further financial and other terms of the deal were not disclosed.
MorphoSys acquired Sloning in October for €19 million ($25 million).